FDA approves first new sunscreen ingredient in 25 years

The U.S. Food and Drug Administration (FDA) has approved bemotrizinol, a new sunscreen ingredient, after a 25-year wait. This marks the first time a sunscreen component has passed through the agency’s streamlined review process, introduced in 2020. Experts say the move will bring long-overdue updates to American sun protection options. Bemotrizinol offers broad-spectrum defence against both UVA and UVB rays while causing minimal skin irritation or absorption. Unlike many existing products, it avoids leaving white streaks and maintains its effectiveness for longer periods. Dr. Jon LaPook highlighted this extended protection as a key advantage over current sunscreens.

The ingredient has received approval for use in adults and children aged six months and older. Initially, DSM Nutritional Products will market it under the brand name Parsol Shield. After an 18-month exclusivity period, other manufacturers will be able to incorporate bemotrizinol into their products. Health and Human Services Secretary Robert F. Kennedy praised the decision as a step forward for sunscreen innovation. David Andrews of the Environmental Working Group echoed this sentiment, noting that Americans have relied on outdated technology for too long. Bemotrizinol’s approval comes after decades of limited progress in U.S. sunscreen formulations.

The FDA’s green light for bemotrizinol introduces a more advanced sun protection option to the American market. Starting with DSM Nutritional Products, the ingredient will soon become available to other brands. Its broad-spectrum coverage and skin-friendly properties address long-standing gaps in U.S. sunscreen choices.